He graduated with a Master in Pharmaceutical Sciences from Ghent University in 1993, and MBA Vlerick Ghent Management School in 1995. He founded Mooss Pharma in 1996, a company which developed human OTC products, divested to Perrigo (Omega Pharma)  in 200. Hereafter, Chris Cardon started a new venture in 2002 with Ecuphar, to capitalise on opportunities in the animal health industry. When Ecuphar was acquired (reverse takeover) by Animalcare Group Plc in 2017 ​(ANCR-LSE), Chris Cardon became C.E.O. of Animalcare Group Plc. Oct 2018, Chris Cardon stepped down, remaining a board member of Animal Group Plc. Soon after, he took on a new venture project namely Ziphius Vaccines.